Kim Hung Lo
About
Kim Hung Lo is a scholar working on Rheumatology, Physiology and Hematology.
According to data from OpenAlex, Kim Hung Lo has authored 54 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Rheumatology, 17 papers in Physiology and 16 papers in Hematology. Recurrent topics in Kim Hung Lo's work include Rheumatoid Arthritis Research and Therapies (17 papers), Autoimmune and Inflammatory Disorders Research (16 papers) and Spondyloarthritis Studies and Treatments (14 papers). Kim Hung Lo is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (17 papers), Autoimmune and Inflammatory Disorders Research (16 papers) and Spondyloarthritis Studies and Treatments (14 papers). Kim Hung Lo collaborates with scholars based in United States, Netherlands and Germany. Kim Hung Lo's co-authors include Eugene S. Chung, Milton Packer, James T. Willerson, Adedigbo A. Fasanmade, Marc A. Judson, Elliot S. Barnathan, Robert P. Baughman, Susan Flavin, Marjolein Drent and Ulrich Costabel and has published in prestigious journals such as The Lancet, Circulation and Journal of Clinical Oncology.
In The Last Decade
Kim Hung Lo
52 papers receiving 3.0k citations
Hit Papers
Peers
Kim Hung Lo
Nadera Sweiss United States
Theodoros Dimitroulas Greece
A. H. Zwinderman Netherlands
Carl Turesson Sweden
Fleur Cohen‐Aubart France
Mami Tamai Japan
John L. Niles United States
Keita Fujikawa Japan
A Meyrier France
Alberto Moggi Pignone Italy
Citations per year, relative to Kim Hung Lo Kim Hung Lo (= 1×)
peers
Nadera Sweiss
Countries citing papers authored by Kim Hung Lo
Since
Specialization
Citations
This map shows the geographic impact of Kim Hung Lo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim Hung Lo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim Hung Lo more than expected).
Fields of papers citing papers by Kim Hung Lo
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Kim Hung Lo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim Hung Lo. The network helps show where Kim Hung Lo may publish in the future.
Co-authorship network of co-authors of Kim Hung Lo
This figure shows the co-authorship network connecting the top 25 collaborators of Kim Hung Lo. A scholar is included among the top collaborators of Kim Hung Lo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kim Hung Lo. Kim Hung Lo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Rosh, Joel R., Dan Turner, Jeffrey S. Hyams, et al.. (2024). Outcomes in Adult Inflammatory Bowel Disease Clinical Trials: Assessment of Similarity Among Participants with Adolescent-onset and Adult-onset Disease. Journal of Crohn s and Colitis. 18(8). 1250–1260.
2.
Hubbard, Jesse J., Kim Campbell, Kathy L. Sivils, et al.. (2023). POS1130 DESIGNING OF A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB, AN FCRN INHIBITOR, IN ADULTS WITH PRIMARY SJÖGREN'S SYNDROME. Annals of the Rheumatic Diseases. 82. 892–893.
3.
Zhang, Nanhua, Steven J. Steiner, Richard B. Colletti, et al.. (2023). Using multiple imputation of real-world data to estimate clinical remission in pediatric inflammatory bowel disease. Journal of Comparative Effectiveness Research. 12(4). e220136–e220136.
4.
Husni, M. Elaine, Atul Deodhar, Sergio Schwartzman, et al.. (2022). Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Arthritis Research & Therapy. 24(1).
5.
Deodhar, Atul, Soumya D. Chakravarty, Natalie J. Shiff, et al.. (2022). Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis. JCR Journal of Clinical Rheumatology. 28(8). 420–423.
6.
Ogdie, Alexis, Jessica A. Walsh, Soumya D. Chakravarty, et al.. (2021). The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial. Clinical Rheumatology. 40(9). 3667–3677.
7.
Mease, Philip J., M. Elaine Husni, Soumya D. Chakravarty, et al.. (2020). Evaluation of Improvement in Skin and Nail Psoriasis in Bio‐naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO‐VIBRANT Study. ACR Open Rheumatology. 2(11). 640–647.
8.
Reveille, John D., Atul Deodhar, Akgun Ince, et al.. (2020). Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial. Value in Health. 23(10). 1281–1285.
9.
Husni, M. Elaine, Arthur Kavanaugh, Eric K. H. Chan, et al.. (2020). Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial. Value in Health. 23(10). 1286–1291.
10.
Mease, Philip J., M. Elaine Husni, Shelly Kafka, et al.. (2020). Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial. Arthritis Research & Therapy. 22(1). 43–43.
11.
Husni, M. Elaine, Arthur Kavanaugh, Frederick T. Murphy, et al.. (2019). Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis. Arthritis Care & Research. 72(6). 806–813.
12.
Deodhar, Atul, John D. Reveille, Diane D. Harrison, et al.. (2017). Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study. The Journal of Rheumatology. 45(3). 341–348.
13.
Baughman, Robert P., Marc A. Judson, Elyse E. Lower, et al.. (2016). Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial.. PubMed. 32(4). 289–95.
14.
Bingham, Clifton O., Michael E. Weinblatt, Chenglong Han, et al.. (2014). The Effect of Intravenous Golimumab on Health-related Quality of Life in Rheumatoid Arthritis: 24-week Results of the Phase III GO-FURTHER Trial. The Journal of Rheumatology. 41(6). 1067–1076.
15.
Rennard, Stephen I., Susan Flavin, Prasheen Agarwal, Kim Hung Lo, & Elliot S. Barnathan. (2012). Long-term safety study of infliximab in moderate-to-severe chronic obstructive pulmonary disease. Respiratory Medicine. 107(3). 424–432.
16.
Wenzel, Sally E., Peter J. Barnes, Eugene R. Bleecker, et al.. (2009). A Randomized, Double-blind, Placebo-controlled Study of Tumor Necrosis Factor-α Blockade in Severe Persistent Asthma. American Journal of Respiratory and Critical Care Medicine. 179(7). 549–558.
17.
Baughman, Robert P., Ralph T. Shipley, Sujal R. Desai, et al.. (2009). Changes in Chest Roentgenogram of Sarcoidosis Patients During a Clinical Trial of Infliximab Therapy. CHEST Journal. 136(2). 526–535.
18.
Baughman, Robert P., Marjolein Drent, Mani S. Kavuru, et al.. (2006). Infliximab Therapy in Patients with Chronic Sarcoidosis and Pulmonary Involvement. American Journal of Respiratory and Critical Care Medicine. 174(7). 795–802.
19.
Kavuru, M S, R. Dubois, Ulrich Costabel, et al.. (2005). CHEST X-RAY ASSESSMENT USING A DETAILED SCORING METHOD IN A RANDOMIZED TRIAL OF INFLIXIMAB IN SUBJECTS WITH CHRONIC PULMONARY SARCOIDOSIS. CHEST Journal. 128(4). 203S–203S.
20.
Drent, Marjolein, Marc A. Judson, Ulrich Costabel, et al.. (2005). RESPONDER ANALYSES IN PATIENTS RECEIVING INFLIXIMAB FOR CHRONIC SARCOIDOSIS WITH PULMONARY INVOLVEMENT. CHEST Journal. 128(4). 316S–316S.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Nadera Sweiss Breakdown of academic impact, for papers by Theodoros Dimitroulas Breakdown of academic impact, for papers by A. H. Zwinderman Breakdown of academic impact, for papers by Carl Turesson Breakdown of academic impact, for papers by Fleur Cohen‐Aubart Breakdown of academic impact, for papers by Mami Tamai Breakdown of academic impact, for papers by John L. Niles Breakdown of academic impact, for papers by Keita Fujikawa Breakdown of academic impact, for papers by A Meyrier Breakdown of academic impact, for papers by Alberto Moggi Pignone